Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revelation Biosciences ( (REVB) ) has provided an announcement.
On September 9, 2025, Revelation Biosciences announced positive results from its Phase 1b PRIME clinical study, which focused on chronic kidney disease patients. The study demonstrated that Gemini, the company’s proprietary formulation, significantly reduced inflammatory activity and restored normal cellular response, indicating its potential to revolutionize the treatment of acute and chronic inflammatory diseases. The results suggest a breakthrough in addressing immune dysregulation in chronic kidney disease, with Gemini showing promise in improving patient outcomes and potentially treating multiple types of inflammation. The study enrolled 40 patients across three U.S. clinics, and the results showed that Gemini was well-tolerated, with no serious adverse events reported.
The most recent analyst rating on (REVB) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. The company has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, prevention for acute kidney injury, and for the treatment of chronic kidney disease.
Average Trading Volume: 171,836
Technical Sentiment Signal: Sell
Current Market Cap: $4.88M
For a thorough assessment of REVB stock, go to TipRanks’ Stock Analysis page.